FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

17 Revised Draft Guidances for Certain Generic Peptide Products

[ Price : $8.95]

FDA posts 17 revised draft product-specific guidances for peptide products, which it touts as a significant advancement in the age...

FDA Accepts for Review Saol Therapeutics SL1009 NDA Resubmission

[ Price : $8.95]

FDA accepts for review a Saol Therapeutics NDA resubmission for SL1009 (sodium dichloroacetate, or DCA), an investigational treatm...

5 Observations in 17-Page Strides Pharma FDA-483

[ Price : $8.95]

FDA releases the 17-page form FDA-483 following a May inspection at Indias Strides Pharma Science drug manufacturing facility in B...

FDA Sends Congress FY 2024 Pediatric Device Approval Report

[ Price : $8.95]

In its report on FY 2024 approvals of medical devices for pediatric uses, FDA says that 19 of the 56 device approvals that year we...

Novel Laboratories FDA-483 Out

[ Price : $8.95]

FDA releases the form FDA-483 with three observations from an inspection at the Novel Laboratories (Lupin) drug manufacturing faci...

FDA Moving to a Shared Services and Inspections Approach

[ Price : $8.95]

NOTUS reports that FDA will reorganize on 10/1 to a shared services model in which administrative functions are centralized, and i...

Controlled Evidence Ecosystem Needed: Expert Column

[ Price : $8.95]

A BioProcess International column says drug companies should design a controlled evidence ecosystem that can demonstrate to FDA in...

Novo Nordisk Seeks Preliminary Injunction Against Lilly

[ Price : $8.95]

Novo Nordisk intensifies pressure against Eli Lilly under a motion seeking a preliminary injunction to stop Eli Lilly's misleading...

CBER Offers Tips for Cell/Gene Therapy BLA Submissions

[ Price : $8.95]

CBER recently used a virtual town hall to urge developers of cell and gene therapies to take advantage of early engagements with t...

FDA Urges Broader Eligibility for Cancer Clinical Trials

[ Price : $8.95]

An FDA final guidance encourages sponsors of oncology clinical trials to broaden eligibility criteria by including more patients w...